- |||||||||| Civacir (hepatitis C immune globulin) / ADMA Biologics, Kedrion
Trial completion: Civacir (clinicaltrials.gov) - Sep 1, 2016 P3, N=80, Completed, Active, not recruiting --> Completed
- |||||||||| Tabrecta (capmatinib) / Incyte, Novartis
Enrollment change, Trial initiation date, Trial withdrawal, Trial primary completion date, Metastases: Study of Efficacy and Safety INC280 in Patients With Advanced Hepatocellular Carcinoma (clinicaltrials.gov) - Sep 1, 2016 P2, N=0, Withdrawn, Recruiting --> Completed | Trial primary completion date: Oct 2013 --> May 2014 N=69 --> 0 | Initiation date: Mar 2014 --> Dec 2016 | Suspended --> Withdrawn | Trial primary completion date: Sep 2016 --> Jul 2019
- |||||||||| aldafermin (NGM282) / NGM Biopharma
Trial completion, Phase classification, Enrollment change, Trial primary completion date: Phase 2b Study of NGM282 Extended Treatment in Patients With Primary Biliary Cirrhosis (clinicaltrials.gov) - Aug 24, 2016 P2b, N=36, Completed, Trial primary completion date: Dec 2016 --> Oct 2017 Recruiting --> Completed | Phase classification: P2 --> P2b | N=45 --> 36 | Trial primary completion date: Jun 2015 --> Feb 2016
- |||||||||| carotuximab IV (ENV-105) / Kairos Pharma
Trial primary completion date, Combination therapy, IO biomarker: Sorafenib and TRC105 in Hepatocellular Cancer (clinicaltrials.gov) - Aug 24, 2016 P1/2, N=44, Recruiting, Recruiting --> Completed | Phase classification: P2 --> P2b | N=45 --> 36 | Trial primary completion date: Jun 2015 --> Feb 2016 Trial primary completion date: Sep 2016 --> Sep 2017
- |||||||||| Enrollment change, Trial termination, MRI: 3-Tesla MRI Response to TACE in HCC (Liver Cancer) (clinicaltrials.gov) - Aug 23, 2016
P=N/A, N=2, Terminated, Active, not recruiting --> Completed N=38 --> 2 | Recruiting --> Terminated; Funding unavailable
- |||||||||| Aphthasol (amlexanox) / Abeona Therap, Esteve
Clinical protocol, Enrollment closed: Efficacy of Amlexanox vs. Placebo in Type 2 Diabetic Patients (clinicaltrials.gov) - Aug 23, 2016 P2, N=40, Active, not recruiting, Trial primary completion date: May 2016 --> Nov 2016 Recruiting --> Active, not recruiting
- |||||||||| pamrevlumab (FG-3019) / FibroGen
Enrollment change, Trial termination, Trial primary completion date: A Study of FG-3019 in Subjects With Liver Fibrosis Due to Chronic Hepatitis B Infection (clinicaltrials.gov) - Aug 16, 2016 P2, N=114, Terminated, Recruiting --> Completed | Initiation date: Jan 2012 --> Sep 2011 | Trial primary completion date: Jan 2015 --> Aug 2014 N=228 --> 114 | Active, not recruiting --> Terminated | Trial primary completion date: Dec 2015 --> Jun 2015; Study terminated due to an unexpected prominent effect of entecavir alone in this patient population.
- |||||||||| Trial completion, Trial primary completion date: Computertomography-guided Wire Marking of the Liver (clinicaltrials.gov) - Aug 16, 2016
P=N/A, N=20, Completed, N=228 --> 114 | Active, not recruiting --> Terminated | Trial primary completion date: Dec 2015 --> Jun 2015; Study terminated due to an unexpected prominent effect of entecavir alone in this patient population. Recruiting --> Completed | Trial primary completion date: Dec 2016 --> Aug 2016
- |||||||||| oxaliplatin / Generic mfg., doxorubicin hydrochloride / Generic mfg.
Enrollment closed, Metastases: Combination Treatment for Advanced Liver Cancer (clinicaltrials.gov) - Aug 2, 2016 P3, N=98, Active, not recruiting, Active, not recruiting --> Completed Recruiting --> Active, not recruiting
- |||||||||| Pegasys (pegylated interferon α -2a) / Roche
Trial completion: Effect of Camel Milk on Chronic Hepatitis C (clinicaltrials.gov) - Jul 30, 2016 P2, N=40, Completed, Active, not recruiting --> Completed | N=6000 --> 35000 | Trial primary completion date: Mar 2017 --> Dec 2015 Recruiting --> Completed
- |||||||||| Enrollment closed, Trial primary completion date: High Fructose Corn Syrup (clinicaltrials.gov) - Jul 24, 2016
P=N/A, N=30, Active, not recruiting, Recruiting --> Active, not recruiting | N=72 --> 50 Recruiting --> Active, not recruiting | Trial primary completion date: Mar 2016 --> Feb 2017
- |||||||||| lenalidomide / Generic mfg.
Enrollment closed, Trial primary completion date, Metastases: Lenalidomide as Second-line Treatment for Advanced Hepatocellular Carcinoma (clinicaltrials.gov) - Jul 23, 2016 P2, N=55, Active, not recruiting, N=252 --> 0 | Not yet recruiting --> Withdrawn | Trial primary completion date: Dec 2016 --> May 2016 Recruiting --> Active, not recruiting | Trial primary completion date: Dec 2015 --> Oct 2016
|